Neutralization of CSF1 and Ad5-HRG treatment.

Slides:

Advertisements

Similar presentations

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Advertisements

CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Effects of SC144 on in vivo ovarian tumor.

Acute, systemic Atg7 deficiency compromises tumorigenesis.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Growth characteristics of strain 22A and its MDH mutant derivatives.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Cytotoxic therapy induces CSF1-dependent macrophage recruitment.

Fig. 5 Local gel scaffold for T cell memory response.

by Seema R. Patel, Ashley Bennett, Kathryn Girard-Pierce, Cheryl L

Volume 21, Issue 4, Pages (November 2014)

Treatment with AZD5363 reduces the proportion of proliferating vascular endothelial cells and following RT, the influx of CD11b+ bone marrow‐derived cells.

The effects of KY19382 on chondrocyte proliferation and differentiation. The effects of KY19382 on chondrocyte proliferation and differentiation. (A) ATDC5.

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

Fig. 3 Reduction of SUPT4H1 or SUPT5H in c9ALS fibroblasts inhibits production of C9orf72 variant 3 mRNA, sense and antisense RNA foci, and DPR proteins.

Effect of CD4+ Th1 cytokines and HER2-targeted antibodies on MHC class I restoration and HER2369–377-CD8+ T-cell targeting of HER2-expressing cancer cells.

IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells. IL-6 signaling affects response to erlotinib in head and neck (HNSCC) cells.

Apoptosis induced by ssHHT in HL60 and its derivative, the HL60/MRP, cells. Apoptosis induced by ssHHT in HL60 and its derivative, the HL60/MRP, cells.

Fig. 3. Neuroprotective effects of silibinin against KA-induced excitotoxicity. (A) Silibinin was intraperitoneally injected for 8 days, starting 1 day.

Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.

Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.

Interference of Kv4 in dorsal neurons (DN1s) does not significantly regulate sleep onset. Interference of Kv4 in dorsal neurons (DN1s) does not significantly.

Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.

The contributions of anti-Ad antibody and T-cell responses to viral clearance in tumor and antitumor efficacy of Ad5 therapy. The contributions of anti-Ad.

TFAP2A knockdown inhibits tumor growth in vivo.

Reduced tumor growth in CCR5-deficient mice is associated with perturbed killing ability of Treg cells. Reduced tumor growth in CCR5-deficient mice is.

PTENP1 sensitizes renal cancer cells to chemotherapy.

The role of p53 in H2O2-mediated cell death of hOGG1-deficient H1299 lung carcinoma p53 null cells. The role of p53 in H2O2-mediated cell death of hOGG1-deficient.

coTCRcys-transduced T cells control tumor growth in vivo.

Tlr4−/− attenuates symptomatic parameters of gut toxicity: diarrhea and weight loss. Tlr4−/− attenuates symptomatic parameters of gut toxicity: diarrhea.

Cytokine expression in the ileum and colon.

CD94/NKG2A+ TILs lack tissue resident CD103 marker.

Accelerated metastasis spread in tumor-bearing mice treated with paclitaxel and anakinra. Accelerated metastasis spread in tumor-bearing mice treated with.

Angiogenesis in tumors formed by cells varying in the expression of CXCR2. Angiogenesis in tumors formed by cells varying in the expression of CXCR2. A,

ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells, and NK cells. ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells,

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

Xenograft regrowth studies.

M-CSFR inhibition decreases tumor-associated macrophages in mesothelioma and improves the DC therapy induced CD8+ T-cell phenotype. M-CSFR inhibition decreases.

Micro-PET/CT images of 64Cu-Sar-chTNT-3 in MAD109-bearing BALB/c mice following VP-16 pretreatment. Micro-PET/CT images of 64Cu-Sar-chTNT-3 in MAD109-bearing.

Ketogenic diets combined with fractionated radiation treatment results in decreased immunoreactive PCNA in tumor tissue. Ketogenic diets combined with.

Three-day biodistribution of 125I-labeled chTNT-3 administered at (A) 1, 2, or 3 days after pretreatment with VP-16 (30 mg/kg) in MAD109 bearing BALB/c.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

Induction of liver NQO1 activity in juvenile female rats treated for 3 d (10 mg/kg qd SERMs or 0.1 mg/kg qd E2 or vehicle control). Induction of liver.

Essential role for the overexpression of type I IFN-related genes in the improved chemotherapeutic response of Stat3−/− tumors. Essential role for the.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Immunohistochemical staining for FOXO3a of breast cancer tumor tissues

Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.

Fig. 5 Increased myometrial cell contractility in response to fetal T cells from preterm infants. Increased myometrial cell contractility in response to.

HMQ1611 inhibited breast tumor growth in mice.

The CD8+ cytotoxic T-cell response in Ron TK−/− hosts in response to tumors is necessary and sufficient to block metastasis. The CD8+ cytotoxic T-cell.

Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.

Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Comparative effect of anti-TIM3 against experimental tumors.

Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.

The effect of TGFβ on the post-RT increase of Tregs in tumors.

PDL192 and inhibit the growth of xenograft tumors.

Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. A,

IL35 regulation of tumor growth is accompanied by suppression of CD4+ effector T-cell activity and expansion of Tregs. IL35 regulation of tumor growth.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3.

Effect of HDC on the ROS production in mouse lungs after melanoma cell inoculation. Effect of HDC on the ROS production in mouse lungs after melanoma cell.

Ex vivo profiling of PD-1 blockade using MDOTS

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

Bezafibrate increases the number of effector CTLs by enhancing their survival capacity and proliferation. Bezafibrate increases the number of effector.

Phenotyping of T cells. Phenotyping of T cells. Circulating lymphocytes from a tumor-naïve C57BL/6 mice (left column) were compared with those from C57BL/6.

Parthenolide inhibits tumor promotion and increases p21 expression in vivo. Parthenolide inhibits tumor promotion and increases p21 expression in vivo.

Presentation transcript:

Neutralization of CSF1 and Ad5-HRG treatment. Neutralization of CSF1 and Ad5-HRG treatment. A, Schematic of treatment strategy. Screws were implanted into the skull and one week later (day 1), 7,500 GL261 cells were inoculated into the caudate nucleus (n = 8–12 mice/group). Ad5 vectors were delivered at day 7 and 13, and the experiment ended 21 days after GL261 cell inoculation. Neutralizing αCSF1 antibody was delivered by intraperitoneal injection at day 2 (1 mg/mouse) and days 6, 10, and 14 (0.5 mg/mouse). B, GL261 tumor sizes at the experimental endpoint expressed as a percentage of buffer-treated tumors with each experimental arm. C, Quantification of CD45+ cells. D, Quantification of CD8a+ cells. Error bars, SEM. Statistical analyses were done using one-way ANOVA followed by Tukey post hoc test (C and D) or one-way ANOVA followed by Bonferroni post hoc and Student t test (B). *, P < 0.05. ns, not significant. Francis P. Roche et al. Mol Cancer Ther 2018;17:1961-1972 ©2018 by American Association for Cancer Research